Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy. The goal of this study was to determine the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-containing immunoconjugates. Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chemical Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/ 4D5. All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities. The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy. The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways. The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/ neu expression level 41.5 Â 10 5 sites per cell. Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins. Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition. Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion. These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate. Immunotoxin orientation can significantly impact the overall functionality and performance of these agents. The recombinant rGel/ 4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administrating to patients, and warrants consideration for further clinical evaluation.
INTRODUCTION
Numerous studies have revealed that Her2/neu overexpression by tumors is a threshold event leading to a highly aggressive cellular phenotype, and therapeutic strategies directed against Her2/neu have rapidly gained recognition. 1, 2 Her2/neu-targeted therapies, including Herceptin and Lapatinib, have significantly improved outcomes in Her2/neu-positive cancers; however, use of these agents can be limited by resistance and tolerability issues. 3, 4 Therefore, there is a need for novel and improved therapeutic approaches targeting Her2/neu.
Immunotoxins are exquisitely powerful cytotoxic proteins. 5, 6 Initial studies focused on constructs created by chemically conjugating an antibody to a protein toxin. 7, 8 With advances in recombinant DNA technology, engineered antibody fragments have been employed to deliver various toxins to Her2/neu-positive tumor cells. 9, 10 There have been numerous studies examining the impact of construct size, antibody affinity and the valency of constructs on overall efficacy. 11, 12 Wels and colleagues 13 suggested that higher avidity and longer residence time of IgG-based immunoconjugates may outweigh the improved tumor penetration of single-chain fragment variable (scFv)-based constructs. However, immunoconjugate development has been hampered by nonspecific toxicity and vascular leak syndrome. 14 In addition, tight junctions between tumor cells and high interstitial tumor pressures could limit successful use of IgG conjugates. 12 Recombinant engineering of immunotoxins has the potential to overcome many of these problems. 12, 15 To improve Her2/ neu-targeting properties, Adams et al. 16 suggested that (scFv) 2 constructs display improved tumor targeting and retention compared with scFv monomers. However, Pastan and colleagues 17 described diabody-based immunotoxins (designated e23 (dsFv) 2 /PE) showing 410-fold greater in vitro cytotoxicity than their monovalent counterparts, but only about 2-fold greater activity in vivo than the monovalent analogs. The high affinity of a diabody may result in formation of a binding-site barrier at the periphery of tumors, which impedes immunotoxin penetration into the tumor mass. 18 Thus, the therapeutic window for Her2/neu targeting may be optimized on design changes instead of confinement to the valency argument.
Recombinant gelonin (rGel), a 29-kDa single-chain ribosomeinactivating protein, has been well established as a highly cytotoxic payload of chemical conjugates or fusion constructs for the treatment of many tumor types. [19] [20] [21] In this study, we utilized Herceptin and its humanized scFv (designated 4D5) to generate a conventional Herceptin/rGel conjugate and corresponding recombinant immunotoxins in two orientations: 4D5/rGel and rGel/4D5. Further characterization studies were performed, including examining the impact of valency and construct orientation on in vitro selectivity, specificity and efficacy of these agents, as well as comparison of their pharmacokinetics, tumor penetration and tumor-targeting efficacy in vivo against tumor xenografts.
RESULTS

Preparation of rGel-based immunotoxins
Antibody-toxin conjugates were generated with a disulfide-based succinimidyl 3-(2-pyridyldithio)propionate (SPDP) linker for facile release of toxin from the antibody carrier ( Figure 1a ). As shown in Figure 1b , the final product contained a mixture of immunoconjugates containing one rGel molecule (major) and two rGel molecules (minor; average molar ratio of 1.21 rGel molecules per antibody). No free Herceptin or free rGel were detected.
The monovalent immunotoxins were generated by fusing scFv 4D5 to the rGel, using the flexible GGGGS linker in two orientations (4D5/rGel and rGel/4D5, Figure 1a ). Both immunotoxins were expressed in E.coli AD494 (DE3) pLysS. Following purification, the immunotoxins were shown to migrate at the expected molecular weight (55 kDa under nonreducing condition) with a purity 495% (Figure 1b) .
Analysis of binding affinity
The binding affinities of monovalent fusion constructs and bivalent chemical conjugates were assessed by enzyme-linked immunosorbent assay using Her2/neu extracellular domain ( Figure 2a ). The apparent binding affinities (Kd) were determined by calculating the concentration of immunotoxins that produced half-maximal specific binding. The monovalent 4D5/rGel and rGel/ 4D5 demonstrated apparent affinities of 0.106 and 0.142 nM, respectively, and the bivalent Herceptin/rGel conjugate had an apparent affinity of 0.201 nM. These results are in agreement with the published affinity values for native Herceptin to the Her2/neu receptor (Kd 0.15 nM). 22 We next tested the cellular Her2/neu-binding activities of these immunotoxins by flow cytometry. As shown in Figure 2b , all the immunotoxins produced higher staining intensities with the Her2/neu-positive SK-OV-3 and BT-474-M1 cells, and displayed a significantly high specificity based on negative MDA-MB-468 cells. These studies confirmed that monovalent fusion constructs display virtually identical binding affinities compared with their original bivalent antibody-based conjugates.
Cell-free protein synthesis inhibitory activity To examine the n-glycosidic activity of rGel component of immunotoxins, these materials were tested by cell-free protein synthesis assay. Inhibition curves for 4D5/rGel, rGel/4D5 and Herceptin/rGel conjugate were compared with that of native rGel (Supplementary Figure S1) 
Cellular uptake and toxin delivery of immunotoxins
We next examined the comparative ability of the immunotoxins to internalize into SK-OV-3, BT-474-M1 and MDA-MB-468 cells. As shown in Figure 2c , after 4 h of exposure, the rGel moiety of all the immunotoxins was observed primarily in the cytosol after treatment of SK-OV-3 or BT-474-M1 (Figures 2d and e) . For the Herceptin/rGel conjugate, there was a rapid initial delivery of free rGel to the cytoplasm within the first hour after drug exposure. The Herceptin/rGel conjugate delivered the greatest amount of rGel to both SK-OV-3 and BT-474-M1 cells. As for monovalent constructs, both fusions displayed similar initial delivery of free rGel in target cells, but rGel/4D5 orientation construct delivered constantly high levels of rGel compared with 4D5/rGel.
In vitro cytotoxicity of immunotoxins
The cytotoxic effects of the constructs were then tested against a variety of different tumor cell lines. As shown in Table 1 , all the immunotoxins demonstrated specific cytotoxicity to cells expressing þ 3 and þ 4 levels of Her2/neu. Targeting indices ranged from 54 to 5120 and from 21 to 2364 for Herceptin/rGel conjugate and rGel/4D5, respectively. The 4D5/rGel construct was comparatively less potent with targeting indices only as high as 213. Figure S2 ), but showed increased sensitivity to these constructs. The cytotoxicity of Herceptin/rGel conjugate and rGel/4D5 outperformed that of 4D5/rGel, which resulted from the improved internalization and intracellular rGel delivery. Antigen-negative cells or those expressing þ 1 and þ 2 levels of Her2/neu were not specifically targeted by any of the constructs.
Effects of immunotoxins on Her2/neu-related signaling pathways We next examined the mechanistic effects of the constructs on Her2/neu-related signaling events in SK-OV-3 cells. As shown in Figure 3a , treatment with Herceptin/rGel conjugate and rGel/4D5 resulted in an impressive inhibition of phosphorylation of Her2/neu, epidermal growth factor receptor (EGFR), Akt and extracellular signal-regulated kinase (ERK), which are critical events in the Her2/neu signaling cascade. In contrast, 4D5/rGel showed a comparatively reduced effect on these pathways. Treatment with these immunotoxins resulted in reduction in the phosphorylation of insulin-like growth factor 1 receptor (IGF1R), a crosstalk partner of Her2/neu. These results suggest a link between downregulation of IGF1R signaling and the antiproliferative effect of anti-Her2/neu immunotoxins against SK-OV-3 cells. The rGel/4D5 construct was comparatively more cytotoxic to target cells than 4D5/rGel, and the improved cytotoxicity coincided with the increased effects on signal transduction.
Immunotoxin effects on Her2/neu-driven multidrug resistance Cells overexpressing Her2/neu often display an increased requirement for the phosphoinositide-3-kinase/Akt signaling pathway in anchorage-independent growth. 23 Currently, we compared the efficacy of chemotherapeutic agents against MCF-7/Her2 cells and parental MCF-7 cells. The MCF-7 cells nominally coexpress Her3 and transfection results in an increased resistance to multiple chemotherapeutic agents (Supplementary Figure S2) . 24 However, we didn't observe the cross-resistance of these cells to rGel-based immunotoxins. As shown in Figure 3b , treatment with Herceptin/ rGel conjugate and rGel/4D5 caused a dose-dependent inhibition of Her2/neu and Her3 phosphorylation, and inhibition of the downstream phosphoinositide-3-kinase/Akt and Ras/ERK cascade.
Cytotoxic activity of immunotoxins against HR cells Acquired resistance to Herceptin therapy can be mediated by concomittent upregulation of Her2/neu downstream signaling pathways and involve constitutive Akt activation, or activation from extrinsic growth factor stimulation. We developed a model of HR variant BT-474-M1 cells. We also demonstrated that addition of EGF or neuregulin-1 growth factors to parental BT-474-M1 cells can prevent the cytotoxic response to Herceptin (Supplementary Figure S3) . However, the treatment of rGel-based immunotoxins displayed impressive cytotoxic effects against all these HR cells (Supplementary Figure S4) .
Mammary BT-474-M1 cells in anchorage-independent threedimensional (3D) culture have been shown to organize into structures resembling in vivo architecture. We examined the growth of BT-474-M1 and the HR cells in response to immunotoxins under the 3D growth on basement membrane. As shown in Figure 4a , all the immunotoxins demonstrated impressive growth inhibition in these 3D models. Treatment with Herceptin/rGel conjugate or rGel/4D5 showed potent cytotoxic effects of both Herceptin-sensitive and HR models, whereas 4D5/rGel only partially inhibited cell growth (Figure 4b) .
We further investigated the signaling pathway of Her2/neu and its crosstalk receptors underlying the inhibitory potential of immunotoxins (Figure 4c ). In either Herceptin-sensitive or HR cells, treatment with immunotoxins led to a potent blockade of phosphorylation of EGFR, Her2/neu and Her3. Similar results were found for inactivation of downstream Akt and ERK in these models. As indicated, Herceptin/rGel conjugate and rGel/4D5 were the most potent at inhibiting phosphorylation of these targets, whereas 4D5/rGel showed comparatively reduced effects.
Activity of immunotoxins against cells expressing intermediate levels of Her2/neu
Previous studies have suggested that targeting of tumors with antibodies or immunotoxins to Her2/neu may result in unexpected organ toxicities due to low levels of Her2/neu expressed on normal tissues. 25, 26 We tested the immunotoxins on ZR-75-1 and BT-20 cells expressing intermediate levels of Her2/neu (B1.5 Â 10 5 sites per cell). 27, 28 As shown in Supplementary  Figure S5A , all the immunotoxins were shown to bind to these Figure S5B) . We were also unable to demonstrate cytotoxic effects of the immunotoxins on Her2/neu-related signaling pathways (Supplementary Figure S5C) . These results indicated that Herceptin-based immunotoxins appeared to show specific cytotoxicity only to tumor cells expressing high levels of Her2/neu (41.5 Â 10 5 sites per cell), but not cells with Her2/neu expression below this threshold.
Immunotoxin pharmacokinetic studies To examine the pharmacokinetic behavior, we utilized fluorescent molecular imaging probe (IRDye 800CW) to label the immunotoxins. The pharmacokinetics of each agent in mice was determined by quantitating the immunotoxin levels in serum by photoluminescence intensity analysis (Supplementary Figure S6) . As shown in Figure 5a , Herceptin/rGel conjugate demonstrated a-and b-phase half-lives of 42 min and 42.7 h, respectively. These clearance kinetics appear to be similar to that of the intact Herceptin IgG. 29, 30 In addition, the monovalent 4D5/rGel and rGel/ 4D5 demonstrated relatively rapid clearance from the circulation with monophasic half-lives of 32.3 min and 34.8 min, respectively. These were similar to the serum half-lives found for scFv-based immunotoxins in mice. 13, 31 Intra-tumor distribution patterns of immunotoxins Dual immunofluorescence studies were performed to evaluate the intratumoral distribution patterns of different immunotoxins in SK-OV-3 xenografts at different times (mouse CD31, red, and rGel, green; Figure 5b ). Immunofluorescence revealed significant differences in the penetration of the immunotoxins from blood vessels into tumor with an apparent valency difference. The scFvbased immunotoxins exhibited the greatest average penetration distance from blood vessels as early as 1 h post injection. Optimal, diffuse distribution occurred throughout the tumor at 24 h after administration. In contrast, the intratumoral migration of Herceptin/rGel appeared to be restricted primarily to the perivascular or intravascular areas of the tumor from 1 to 24 h after administration. At 72 h, the immunoconjugate had disseminated from vascular lumen. Quantitative analysis (Figure 5c ) supports the observation that monovalent fusions achieve maximal tumor distribution by 24 h, and clear from the tumor thereafter. In contrast, Herceptin/rGel conjugate increases in tumors over the 72-h observation period. These findings suggest that high interstitial pressures in tumors may limit the diffusion of full-length antibodies from the blood vessels into the tumor. 32, 33 In contrast, smaller fusion constructs display faster tumor uptake and clearance patterns, and provide uniform tumor penetration.
Antitumor activity of immunotoxins in xenograft models
We further evaluated the ability of anti-Her2/neu immunotoxins to inhibit the growth of SK-OV-3 tumor xenografts. As shown in Figure 6a , a dose-dependent inhibition of tumor growth was observed. For Herceptin/rGel conjugate, total doses of 10 mg/kg caused a 20-day tumor growth delay, whereas 20 or 40 mg/kg doses resulted in a 440-day growth delay until the animals were killed. The groups treated with 20 or 40 mg/kg rGel/4D5 showed a 
DISCUSSION
Initial studies of anti-Her2/neu rGel-based fusion constructs focused on the characterization of target specificity of scFv, and linker design between scFv and rGel. 34, 35 However, until now, there are no in-depth reports of the relationship of rGel-based fusion constructs in regard to large chemical conjugates. To the best of our knowledge, this is the first comprehensive examinations of the characteristics of rGel-based monovalent immunotoxin design compared with bivalent immunoconjugates with respect to the impact of valency and toxin delivery, cytotoxic activity, pharmacokinetics, tumor penetration and comparative antitumor efficacy in tumor xenograft models.
Previous studies suggest that bivalent constructs have higher affinity and are more effective delivery vehicles for toxins when compared with monovalent fusion designs. 17, 36 In contrast, our studies demonstrated that both monovalent and bivalent immunotoxins displayed comparable Her2/neu-binding affinity. We did find that the bivalent conjugate was more effective compared with monovalent constructs in terms of delivery of rGel to the intracellular compartment. However, the magnitude of the increased delivery of rGel toxin did not appear to correlate with a corresponding increase in relative in vitro cytotoxicity, as both Herceptin/rGel conjugate and rGel/4D5 fusion demonstrate comparable IC 50 values against target cells. These studies may suggest that subcellular trafficking and delivery to the ribosomal compartment may also have pivotal roles in the overall cytotoxic potential of these agents. Once these constructs bind to the extracellular domain, Her2/ neu endocytosis may result in either recycling from endosomes back to the plasma membrane, releasing the target molecule out of cells, or degradation of the protein within target cells. A comparison of 4D5/rGel and rGel/4D5 orientations demonstrated that both constructs bound to tumor cells to an equivalent extent, but we found a comparatively greater level of intracellular rGel after exposure to rGel/4D5. These studies suggest that the orientation of the rGel/4D5 construct appears to more readily promote the intracellular trafficking and release of the rGel payload from the construct compared with the 4D5/rGel orientation. The mechanisms underlying the observed orientation specificity of this construct are not clear, but this may be a feature of the Her2/neu target itself, a subtle characteristic of the antibody utilized, or it may be related to the rGel payload employed.
Our antitumor efficacy studies demonstrated that Herceptin/ rGel conjugate in the SK-OV-3 xenograft model was highly effective at this schedule and at doses ranging from 10 to 40 mg/kg. Treatment with rGel/4D5 fusion at doses above 20 mg/ kg led to significant inhibition of tumor growth similar to that observed for the immunoconjugate. Considering the significant differences in serum half-lives observed between both agents (0.5 h vs 43 h for rGel/4D5 and Herceptin/rGel conjugate, respectively), these results suggested that the advantages of uniform and rapid tumor penetration of small molecules may outweigh the advantages of IgG molecules with higher valency or longer residence time. Multiple administrations resulting in higher concentrations of rGel/4D5 with a uniform penetration into tumor tissue may be an effective strategy to overcome the limitations of rapid clearance. In addition, the higher toxicity highlighted an additional point regarding Herceptin/rGel conjugate compared with rGel/4D5. Characteristics of rGel/4D5, such as uniform tumor penetration and rapid clearance, may reduce unwanted toxicity to normal tissue in patient treatment, and may warrant consideration for continued clinical trial.
Overexpression of Her2/neu and the associated increase in Her2/ neu-mediated signaling has been implicated in conferring therapeutic resistance in various tumor types. 23, 24 Of critical importance is the observed potency and lack of cross-resistance of rGel-based immunotoxins against cells resistant to conventional chemotherapeutic agents or therapeutic antibodies. The mechanistic studies demonstrated that anti-Her2/neu immunotoxins could efficiently downregulate phosphorylation of Her2/neu and its associated pathways, resulting in inhibition of both phosphoinositide-3-kinase/Akt and Ras/ERK signaling pathways. As immunotoxin treatment also impacts EGFR-, Her3-and IGF1R-signaling pathways, the inhibition of Her2/neu signaling may be partially associated with immunotoxin cytotoxic effects.
The Her2/neu receptor is present at low levels on a number of normal tissues, including epithelia of the gastro-intestinal, respiratory and urogenital tracts, mammary tissue, cardiac and hepatic cells. 37 Previous studies with anti-Her2/neu immunotoxins erb-38 or (FRP)-ETA have shown potent antitumor activity in animal models, but unexpected hepatotoxicity in patients owing to the presence of Her2/neu on hepatocytes (B0.5 Â 10 5 sites per cell). 25, 38, 39 The binding affinity were 27 Â 10 À 9 M for erb-38 17 and 6.5 Â 10 À 9 M for (FRP5)-ETA. 40 This suggests that Her2/neutargeted immunotoxins with affinities in the nanomolar range may target both tumor and normal cells expressing low antigen levels. In our studies, Herceptin-based immunotoxins with subnanomolar affinity (K d B10 À 10 M) showed specific cytotoxicity to Her2/neu-overexpressing cancer cells, but not cells expressing Her2/neup1.5 Â 10 5 sites per cell. Therefore, these constructs have a distinct advantage over the reported anti-Her2/neu immunotoxins, at minimizing toxicity by reducing nonspecific organ damage, suggesting the potential for clinical evaluation.
In conclusion, we developed a number of novel rGel-based immunotoxins containing bivalent-or monovalent-targeting antibodies. These immunotoxins showed specific activity against cancer cells expressing high level of Her2/neu. Resistance to Herceptin or chemotherapeutic agents did not appear to impact immunotoxin efficacy. Although Herceptin/rGel conjugate showed a long circulation half-life and impressive antitumor efficacy, the rGel/4D5 construct demonstrated excellent tumor penetration and displayed comparable cytotoxic efficacy in vitro and in vivo against tumor xenograft models. These studies provide a new and comprehensive understanding of monovalent vs bivalent immunotoxins, and may have a significant impact on the design of future rGel-based immunotoxins. 
MATERIALS AND METHODS
Preparation of Herceptin/rGel conjugate
The details for the generation of antibody/rGel chemical conjugates have been published elsewhere. 30 For the Herceptin/rGel conjugate, rGel was covalently linked to Herceptin, using the heterobifunctional cross-linking reagent succinimidyl 3-(2-pyridyldithio)propionate (SPDP).
Preparation of 4D5-based fusion constructs
The sequence of scFv 4D5 was derived from the published Herceptin light and heavy-chain variable domain sequences. 22 We generated fusion constructs with rGel in two orientations (designated 4D5/rGel and rGel/ 4D5. The immunotoxins were then expressed in E.coli AD494 (DE3) pLysS and purified by IMAC as previously reported. 34 Determination of binding affinity Evaluation of the Her2/neu-binding affinity was measured by enzymelinked immunosorbent assay: 96-well enzyme-linked immunosorbent assay plates were coated with Her2/neu extracellular domain. Then, a series of diluted immunotoxins were added to each well. Anti-rGel antibody and horseradish peroxidase-conjugated secondary antibody was used as a tracer.
Evaluation of cellular Her2/neu binding by flow cytometry was performed on Her2/neu-positive (SK-OV-3 or BT-474-M1) and -negative (MDA-MB-468) cells. Cells were incubated with 25 nM immunotoxins at 4 1C. After washes, anti-rGel antibody was added, which was chased by fluorescein isothiocyanate-labeled secondary antibody. Detection of bound immunotoxins was performed by flow cytometry on XL-MCL Flow Cytometer (Beckman Coulter, Miami, FL, USA).
Reticulocyte lysate in vitro translation assay
The n-glycosidase activity of the rGel component of the various constructs was assessed using a cell-free protein synthesis system by rabbit reticulocytes lysate kit (Promega, Madison, WI, USA). 20 
Internalization analysis
Immunofluorescence-based internalization studies were performed on SK-OV-3, BT-474-M1 and MDA-MB-468 cells. 34 After drug treatment, the optimization of anti-Her2/neu immunotoxins Y Cao et al cells were subjected to anti-rGel antibody (fluorescein isothiocyanateconjugated secondary antibody). Nuclei were counterstained with propidium iodine. Visualization of immunofluorescence was performed with a confocal laser-scanning microscope Zeiss LSM510 (Carl Zeiss GmbH, Jena, Germany).
Intracellular behavior study
The intracellular behavior of each immunotoxin was analyzed on SK-OV-3 and BT-474-M1 cells. After incubation for various times, the cells were treated with acidic glycine buffer (500 mM NaCl and 0.1 M glycine (pH 2.5)) to strip cell-surface-bound proteins, and lysed in lysis buffer (10 mM Tris-HCl (pH8.0), 60 mM KCl, 1 mM EDTA, 1% NP40 and 1% SDS). Cytosolic fractions were analyzed by western blot using anti-rGel antibody. Data are presented as the relative density of total rGel signal or free rGel signal normalized to b-actin. Relative protein quantification was done using AlphaEaseFC software version 4.0.1 (Alpha Innotech Corp., San Leandro, CA, USA).
In vitro cytotoxicity assays
Log-phase cells in monolayer culture were treated with various immunotoxins or rGel at 37 1C for 72 h, and the cell viability was determined by using crystal violet staining method. 3D cell culture BT-474-M1 and its derived HR cells were placed on top of laminin-rich matrix (Matrigel, BD Biosciences, San Jose, CA, USA), and maintained in Dulbecco's modified Eagle's medium with 5% Matrigel, 41 with or without the presence of 20 ng/ml EGF or 50 ng/ml NRG-1. Cells were treated with each drug on day 3, and culture medium was refreshed every 3 days. The analysis of 3D Matrigel growth was evaluated on day 12 for more than 25 spheroids under each condition. ImageJ (http://rsbweb.nih.gov/ij/) was used for the analysis of spheroid area from phase-contrast photos.
Pharmacokinetic studies
Immunotoxins were labeled with infrared dye reagent IRDye 800CW according to Protein Labeling Manual (Li-Cor Biosciences, Lincoln, NE, USA). Balb/c mice were intravenously injected with 2 nM IRDye800 equivalent of fluorescent probes, and blood samples were obtained at different times post injection (3, 15 and 30 min, and 1, 2, 4, 8 and 24 h). The photoluminescence intensity of the samples was quantitated using an IVIS optical imaging system (Xenogen Corp., Alameda, CA, USA). The circulation half-life was calculated by fitting the data to a one-phase exponential decay equation for monovalent fusions and a two-phase exponential decay equation for bivalent conjugate (GraphPad Prism, version 5.04, GraphPad Software, Inc., San Diego, CA, USA).
Tumor penetration studies
Balb/c nude mice were injected subcutaneously with SK-OV-3 cells (5 Â 10 6 cells/mouse). When the tumor reached B150 mm 3 , animals were intravenously injected with 150 mg rGel or monovalent immunotoxins (4D5/rGel or rGel/4D5), or 500 mg Herceptin/rGel conjugate. After 1, 24 and 72 h, the mice were killed and tumor samples were collected and frozen for section slides. The slides were incubated with anti-rGel antibody (fluorescein isothiocyanate-conjugated secondary antibody), and antimouse CD31 antibody (phycoerythrin-conjugated secondary antibody). Immunofluorescence observation was performed under a Nikon Eclipse TS-100 fluorescence microscope (Nikon Corp., Tokyo, Japan). Quantitative analysis on the tissue slides were measured by the software ImageJ. Statistical results were obtained from two tumor slides, and four view regions were taken from each slide.
In vivo efficacy studies Balb/c nude mice inoculated with SK-OV-3 cells were assigned into treatment groups, such that by day 10 post inoculation, the mean tumor volume for each group was B100 mm 3 . Mice were treated every other day for six times by intravenous injection of phosphate-buffered saline, rGel (20 mg/kg), Herceptin (40 mg/kg) and various immunotoxins (4D5/rGel, rGel/4D5 and Herceptin/rGel conjugate, 10, 20 and 40 mg/kg, respectively). All treatment groups consisted of five animals per group, and tumor size was monitored twice weekly using caliper measurement.
Immunohistochemistry SK-OV-3 xenografted mice were treated with phosphate-buffered saline, 20 mg/kg of rGel, 4D5/rGel or rGel/4D5 and 40 mg/kg of Herceptin or Herceptin/rGel conjugate. Tumor samples were collected and fixed in 4% formaldehyde and paraffin embedded. The immunohistochemistry was applied with antibodies against p-Her2/neu (Tyr877), p-ERK (Thr 177/Thr 160; Santa Cruz Biotechonology) and p-Akt (Ser473; Cell Signaling Technology) to detect the target phosphorylation level. Antibody binding was revealed by addition of 3.3 0 -diaminobenzidine substrate. Tissues were further counterstained with hematoxylin. Immunohistochemistry staining was examined using a Nikon Eclipse TS-100 microscope (Nikon).
